Your browser doesn't support javascript.
loading
Beta-blocker supplementation of standard drug treatment for schizophrenia.
Cheine, M; Ahonen, J; Wahlbeck, K.
Afiliación
  • Cheine M; Department of Psychiatry, University of Helsinki, Lapinlahdentie, Helsinki University Central Hospital, Helsinki, Finland, FIN-00029. maxim.cheine@huch.fi
Cochrane Database Syst Rev ; (3): CD000234, 2001.
Article en En | MEDLINE | ID: mdl-11686955
ABSTRACT

BACKGROUND:

Many people with schizophrenia or similar severe mental disorders do not achieve a satisfactory treatment response with ordinary antipsychotic drug treatment. In these cases, various add-on medications are used, among them beta-adrenergic receptor antagonists (beta-blockers).

OBJECTIVES:

To evaluate the clinical effects of beta-blockers as an adjunct to antipsychotic medication in schizophrenia or similar severe mental disorders. SEARCH STRATEGY Publications in all languages were searched from the following databases Biological Abstracts (1982-2000), The Cochrane Library (Issue 3, 2000), The Cochrane Schizophrenia Group's Register (November 2000), EMBASE (1980-2000), LILACS (1982-1996), MEDLINE (1966-2000) and PsycLIT (1974-2000). Reference sections of included papers were screened. SELECTION CRITERIA All randomised controlled trials comparing beta-blockers with placebo as an adjunct to conventional antipsychotic medication for those with schizophrenia. DATA COLLECTION AND

ANALYSIS:

Studies were selected and then data extracted, independently, by at least two reviewers. Odds ratios (OR) and 95% confidence intervals (CI) of homogeneous dichotomous data were calculated using the Peto method. A random effects model was used for heterogeneous dichotomous data. Weighted mean differences were calculated for continuous data. MAIN

RESULTS:

Currently the review includes five studies but data are poorly presented and there is no evidence of any effect of beta-blockers as an adjunct to conventional antipsychotic medication. REVIEWER'S

CONCLUSIONS:

At present beta-blockers cannot be recommended in the treatment of schizophrenia. Any possible benefit of adjunctive beta-blockers is obscured by poor reporting within included studies. Existing data on beta-blockers as adjunctive medication to antipsychotics for those with schizophrenia should be collected and re-analysed in order to allow confident conclusions about the effect of this treatment or the need for further trials.
Asunto(s)
Buscar en Google
Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esquizofrenia / Antagonistas Adrenérgicos beta Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Cochrane Database Syst Rev Asunto de la revista: PESQUISA EM SERVICOS DE SAUDE Año: 2001 Tipo del documento: Article Pais de publicación: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM
Buscar en Google
Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esquizofrenia / Antagonistas Adrenérgicos beta Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Cochrane Database Syst Rev Asunto de la revista: PESQUISA EM SERVICOS DE SAUDE Año: 2001 Tipo del documento: Article Pais de publicación: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM